Enhanced Outpatient Symptom Management to Reduce Acute Care Visits Due to Chemotherapy-Related Adverse Events
Public ClinicalTrials.gov record NCT05038254. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
There Is No Place Like Home- A Pragmatic Effectiveness Trial of Technology-Enhanced Outpatient Symptom Management to Reduce Acute Care Visits Due to Chemotherapy-Related Adverse Events
Study identification
- NCT ID
- NCT05038254
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Not applicable
- Enrollment
- 750 participants
Conditions and interventions
Conditions
- Clinical Stage IV Esophageal Adenocarcinoma AJCC v8
- Clinical Stage IV Esophageal Squamous Cell Carcinoma AJCC v8
- Clinical Stage IV Gastric Cancer AJCC v8
- Clinical Stage IVA Esophageal Adenocarcinoma AJCC v8
- Clinical Stage IVA Esophageal Squamous Cell Carcinoma AJCC v8
- Clinical Stage IVA Gastric Cancer AJCC v8
- Clinical Stage IVB Esophageal Adenocarcinoma AJCC v8
- Clinical Stage IVB Esophageal Squamous Cell Carcinoma AJCC v8
- Clinical Stage IVB Gastric Cancer AJCC v8
- Metastatic Colon Carcinoma
- Metastatic Esophageal Carcinoma
- Metastatic Gastric Carcinoma
- Metastatic Liver Carcinoma
- Metastatic Malignant Digestive System Neoplasm
- Metastatic Malignant Small Intestinal Neoplasm
- Metastatic Malignant Thoracic Neoplasm
- Metastatic Pancreatic Carcinoma
- Metastatic Rectal Carcinoma
- Pathologic Stage IV Esophageal Adenocarcinoma AJCC v8
- Pathologic Stage IV Esophageal Squamous Cell Carcinoma AJCC v8
- Pathologic Stage IV Gastric Cancer AJCC v8
- Pathologic Stage IVA Esophageal Adenocarcinoma AJCC v8
- Pathologic Stage IVA Esophageal Squamous Cell Carcinoma AJCC v8
- Pathologic Stage IVB Esophageal Adenocarcinoma AJCC v8
- Pathologic Stage IVB Esophageal Squamous Cell Carcinoma AJCC v8
- Postneoadjuvant Therapy Stage IV Esophageal Adenocarcinoma AJCC v8
- Postneoadjuvant Therapy Stage IV Esophageal Squamous Cell Carcinoma AJCC v8
- Postneoadjuvant Therapy Stage IV Gastric Cancer AJCC v8
- Postneoadjuvant Therapy Stage IVA Esophageal Adenocarcinoma AJCC v8
- Postneoadjuvant Therapy Stage IVA Esophageal Squamous Cell Carcinoma AJCC v8
- Postneoadjuvant Therapy Stage IVB Esophageal Adenocarcinoma AJCC v8
- Postneoadjuvant Therapy Stage IVB Esophageal Squamous Cell Carcinoma AJCC v8
- Stage IV Colon Cancer AJCC v8
- Stage IV Hepatocellular Carcinoma AJCC v8
- Stage IV Pancreatic Cancer AJCC v8
- Stage IV Rectal Cancer AJCC v8
- Stage IV Small Intestinal, Esophageal, Colorectal, Mesenteric, and Peritoneal Gastrointestinal Stromal Tumor AJCC v8
- Stage IVA Colon Cancer AJCC v8
- Stage IVA Hepatocellular Carcinoma AJCC v8
- Stage IVA Rectal Cancer AJCC v8
- Stage IVB Colon Cancer AJCC v8
- Stage IVB Hepatocellular Carcinoma AJCC v8
- Stage IVB Rectal Cancer AJCC v8
- Stage IVC Colon Cancer AJCC v8
- Stage IVC Rectal Cancer AJCC v8
Interventions
- Best Practice Other
- Patient Monitoring Procedure
- Questionnaire Administration Other
Other · Procedure
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 11, 2021
- Primary completion
- Jan 30, 2026
- Completion
- Jan 30, 2026
- Last update posted
- Aug 11, 2025
2021 – 2026
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| M D Anderson Cancer Center | Houston | Texas | 77030 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Recently updated Clinical Stage IV Esophageal Adenocarcinoma AJCC v8 trials
Other public records listing Clinical Stage IV Esophageal Adenocarcinoma AJCC v8. Sorted by last update posted; newest first. Not a recommendation.
- NCT07594548: Futibatinib With Paclitaxel and Ramucirumab for the Treatment of Locally Advanced or Unresectable Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Not yet recruiting
- NCT06203600: Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial Recruiting
- NCT04314401: National Cancer Institute "Cancer Moonshot Biobank" Active, not recruiting
- NCT05677490: mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma Recruiting
- NCT04248452: Testing the Addition of Radiotherapy to the Usual Treatment (Chemotherapy) for Patients With Esophageal and Gastric Cancer That Has Spread to a Limited Number of Other Places in the Body Active, not recruiting
- NCT04460937: Testing the Addition of an Anti-cancer Drug, Adavosertib, to Radiation Therapy for Patients With Incurable Esophageal and Gastroesophageal Junction Cancers Active, not recruiting
All Clinical Stage IV Esophageal Adenocarcinoma AJCC v8 trials →
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05038254, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 11, 2025 · Synced May 19, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05038254 live on ClinicalTrials.gov.